CIK 0001479419
- Non-accelerated filer
- Smaller reporting company
KALA BIO, Inc.
Sign in to watch- Ticker
- KALA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 270604595
- Phone
- +1 781-996-5252
- Business address
- 1167 MASSACHUSETTS AVENUE, ARLINGTON, MA, 02476
- Former names
- KALA BIO, Inc., Kala Pharmaceuticals, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 46 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-06-16 | Rosen Howard B Director | Grant or award · Stock Option (right to buy) | +40,000 | 40,000 | ||
| 2022-06-16 | PERRY GREGORY D Director | Grant or award · Stock Option (right to buy) | +40,000 | 40,000 | ||
| 2022-06-16 | Paull Robert Bradley Director | Grant or award · Stock Option (right to buy) | +40,000 | 40,000 | ||
| 2022-06-16 | KOVEN ANDREW I Director | Grant or award · Stock Option (right to buy) | +50,000 | 50,000 | ||
| 2022-05-26 | RA CAPITAL MANAGEMENT, L.P. 10% owner | Sale | −1,005,686 | $0.36 | $366K | 7,039,613 |
| 2022-05-25 | RA CAPITAL MANAGEMENT, L.P. 10% owner | Sale | −1,434,509 | $0.42 | $602K | 8,045,299 |
| 2022-05-24 | RA CAPITAL MANAGEMENT, L.P. 10% owner | Sale | −144,805 | $0.51 | $74K | 9,479,808 |
| 2022-05-23 | RA CAPITAL MANAGEMENT, L.P. 10% owner | Sale | −1,250,000 | $0.65 | $813K | 9,624,613 |
| 2022-02-15 | Kharabi Darius CHIEF BUSINESS OFFICER | Other disposition | −9 | 15,430 | ||
| 2022-01-04 | Reumuth Mary CHIEF FINANCIAL OFFICER | Sale | −2,850 | $1.30 | $4K | 133,208 |
| 2022-01-04 | Brazzell Romulus K | Sale | −3,504 | $1.30 | $5K | 288,345 |
| 2022-01-04 | Bazemore Todd | Sale | −3,454 | $1.30 | $4K | 118,591 |
| 2022-01-04 | Iwicki Mark T CHIEF EXECUTIVE OFFICER | Sale | −9,518 | $1.30 | $12K | 259,158 |
| 2022-01-04 | Trachtenberg Eric | Sale | −2,850 | $1.30 | $4K | 113,816 |
| 2022-01-03 | Reumuth Mary CHIEF FINANCIAL OFFICER | Grant or award · Stock Option (right to buy) | +153,000 | 153,000 | ||
| 2022-01-03 | Brazzell Romulus K | Grant or award · Stock Option (right to buy) | +238,000 | 238,000 | ||
| 2022-01-03 | Bazemore Todd | Grant or award · Stock Option (right to buy) | +238,000 | 238,000 | ||
| 2022-01-03 | Iwicki Mark T CHIEF EXECUTIVE OFFICER | Grant or award · Stock Option (right to buy) | +775,000 | 775,000 | ||
| 2022-01-03 | Trachtenberg Eric | Grant or award · Stock Option (right to buy) | +153,000 | 153,000 | ||
| 2021-11-15 | Kharabi Darius CHIEF BUSINESS OFFICER | Grant or award | +295,657 | 295,657 |
Page 13 of 19 · 378 trades